About Tivic Health Systems, Inc. - Common stock (TIVC)
Tivic Health Systems, Inc. is a medical technology company focused on developing innovative solutions for chronic conditions affecting the upper respiratory tract. The company specializes in advanced neuromodulation therapies, which leverage electrical stimulation to address symptoms associated with conditions such as rhinitis and sinusitis. By utilizing its proprietary technology, Tivic Health aims to enhance patient quality of life through non-invasive treatment options that offer an alternative to traditional medication. Their commitment to research and development positions them at the forefront of transforming how patients manage their health. Read More
Tivic Health® Systems, Inc. (Nasdaq: TIVC), a diversified therapeutics company, today announced it is expanding its intellectual property portfolio with the recent filing of two additional patent applications with the United States Patent and Trademark Office.
Tivic Health® Systems, Inc. (Nasdaq: TIVC), a diversified immunotherapeutics company, today announced that it will report its third quarter results for 2025 via pre-recorded conference call and webcast on Friday, November 14, 2025 at 1:30 PM PT / 4:30 PM ET.
Tivic Health® Systems, Inc. (Nasdaq: TIVC), a diversified immunotherapeutics company, today announced that CEO, Jennifer Ernst, will participate in the eighth annual Constellation Forum, a global conversation on Bioelectronic Medicine. She will join other leaders in the field to discuss the opportunities for advancing bioelectronic medicine.
Tivic Health® Systems, Inc. (Nasdaq: TIVC), a diversified immunotherapeutics company, today announced that the company’s CEO will present during the Emerging Growth virtual conference set to take place on September 24 & 25, 2025.
As the regular session of the US market concludes on Wednesday, let's get an insight into the after-hours session and identify the stocks leading the pack in terms of gains and losses.
Tivic Health® Systems, Inc. (Nasdaq: TIVC), a diversified immunotherapeutics company, today announced that it has completed verification of its Entolimod™ cell line, the first step in establishing Current Good Manufacturing Practices (CGMP) in preparation for a Biologics License Application, or BLA.
Tivic Health® Systems, Inc. (Nasdaq: TIVC), a diversified immunotherapeutics company, today announced it has received, from Statera Biopharma, two investigational new drug applications (INDs) for its lead candidate, Entolimod™. The two INDs cover the use of Entolimod to treat acute radiation syndrome, including both hematopoietic (ARS-H) and gastrointestinal (ARS-GI) sub-syndromes, and the use of Entolimod to treat advanced cancers, including as an anti-tumor agent and for conditions resulting from cancer treatments.
As the regular session of the US market on Friday comes to an end, let's delve into the after-hours session and discover the top gainers and losers shaping the post-market sentiment.
Tivic Health® Systems, Inc. (Nasdaq: TIVC), a diversified therapeutics company, is proud to announce it advanced discussions with key US Government agencies through its participation in the 2025 Military Health System Research Symposium (MHSRS), held August 4-7, 2025, in Kissimmee, Florida. The MHSRS is the Department of Defense’s premier scientific meeting that brings together military, academic, and industry experts to discuss medical research and innovation in support of warfighter health and readiness.
Tivic Health® Systems, Inc. (NASDAQ: TIVC), a diversified immunotherapeutics company, today announced financial results for the second quarter and six months ended June 30, 2025.
Tivic Health® Systems, Inc. (Nasdaq: TIVC), a diversified immunotherapeutics company developing treatments that stimulate immune pathways to treat disease, today announced that it will report its second quarter results for 2025 via pre-recorded conference call and webcast on Thursday, August 14, 2025 at 1:30 PM PT / 4:30 PM ET.
